Angioimmunoblastic T-Cell Lymphoma (AILT)/ Single User License:
Immunoblastic Lymphadenopathy Market USD 4315.5
Global Industry Analysis, Size, Share, Growth,
Flat 10% Discount!!
Free Customization as per your requirement
Trends and Forecast 2014 - 2020
Transparency Market Research
90, State Street, Suite 700.
Albany, NY 12207
You will get Custom Report at Syndicated Report
Report will be delivered with in 15-20 working days
Angioimmunoblastic T-Cell Lymphoma (AILT) also known as Immunoblastic Lymphadenopathy is a grown T-cell lymphoma of blood distinguished
by a polymorphous lymph node penetrate resulting significant increase in follicular dendritic cells (FDCs) and high endothelial venules (HEVs) with
systemic involvement. Clinically this disorder is characterized by generalized lymphadenopathy and high fever. This disorder progresses in series
of diseases such as cutaneous involvement, hepatosplenomegaly, hemolytic anemia and polyclonal hypergammaglobulinemia. The symptoms
observed in a patient suffering from angioimmunoblastic T-cell lymphoma are weight loss, polyclonal hyperglobulinemia, hepatomegaly and
generalized adenopathy.The other problems accompanying angioimmunoblastic T-cell lymphoma (AILT)/ immunoblastic lymphadenopathy are
multicentric giant lymph node hyperplasia, acute viral lymphadenitis, hypersensitivity syndrome, lymphoma, leukemia, Crohn’s disease and a
typical linear immunoglobulin A dermatosis. The standard staging of angioimmunoblastic T-cell lymphoma (AILT) is explained with Ann Arbor
system that was developed for Hodgkin disease. The stages involved in angioimmunoblastic T-cell lymphoma (AILT) are as follows:
Stage I - Involvement of a single lymph node region
Stage II - Involvement of two or more lymph node regions on the same...